Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + ezetimibe + rosuvastatin
- Development stage
- Unknown
- Lead developer
- LG Chem
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
rosuvastatin-LG Chem-Hypertension-Dyslipidemia refers to a series of fixed-dose combination (FDC) therapies developed by LG Chem to treat patients with co-existing hypertension and dyslipidemia. The program includes dual combinations such as Rovatitan (rosuvastatin and valsartan) and Zemiro (rosuvastatin and ezetimibe), as well as a triple combination marketed as Rovatitan Plus (rosuvastatin, ezetimibe, and valsartan). These products combine the lipid-lowering effects of rosuvastatin (an HMG-CoA reductase inhibitor) and ezetimibe (a cholesterol absorption inhibitor) with the antihypertensive effects of valsartan (an angiotensin II receptor blocker). By consolidating these treatments into a single daily tablet, LG Chem aims to simplify complex medication regimens, improve patient compliance, and enhance the management of cardiovascular risk factors. The triple combination was evaluated in Phase 1 studies (e.g., LGEV1801 and LGEV1802) to confirm the absence of significant drug-drug interactions between the components.
- Brand names
- Rovatitan PlusRovatitanZemiro
- Other names
- Rosuvastatin/Ezetimibe/ValsartanLGEV1801 + LGEV1802
02
Targets
NPC1L1 (Niemann-pick C1-Like 1 transporter)AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on valsartan + ezetimibe + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + ezetimibe + rosuvastatin.